|
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We previously showed that an MHC class I-restricted epitope of myelin basic protein (MBP) is presented in the CNS during CD4+ T cell-initiated EAE.
|
31573979 |
2020 |
|
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We then monitored the thickness of the retinal layers in different EAE models: in wild-type (WT) C57Bl/6J mice immunized with myelin oligodendrocyte glycoprotein peptide (MOG<sub>35-55</sub>) or with bovine myelin basic protein (MBP), in TCR<sup>2D2</sup> mice immunized with MOG<sub>35-55</sub>, and in SJL/J mice immunized with myelin proteolipid lipoprotein (PLP<sub>139-151</sub>).
|
31684959 |
2019 |
|
Encephalomyelitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Induction of EAE caused a significant decrease of myelin basic protein expression in the hindbrain of disease affected WT mice in comparison to Cpt1a P479L mice.
|
31527712 |
2019 |
|
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrated that immunisation with a high dose of myelin basic protein (MBP) peptide and complete Freund's adjuvant failed to effectively initiate EAE, in contrast to low dose MBP peptide immunisation which readily induced disease.
|
30485411 |
2019 |
|
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated the effects of Oenothera biennis L. and Hypericum perforatum L. extracts on brain tissue histopathology, myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP), total antioxidant status (TAS), total oxidant status (TOS) and oxidative stress index (OSI) in mice with experimental autoimmune encephalomyelitis (EAE).
|
30957550 |
2019 |
|
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Male Lewis rats were immunized with myelin basic protein (MBP) peptide to establish an EAE model and then treated with three doses of PZH.
|
29682587 |
2018 |
|
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since histone deacetylase (HDAC) inhibitors have been previously shown to improve neurological disability, we also show that treatment with trichostatin A (a HDAC inhibitor) improves the NDS of EAE mice but does not change MBP acetylation.
|
29111742 |
2018 |
|
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
During the acute EAE phase (7-20 days after immunization), catalytic antibodies efficiently hydrolysing myelin basic protein (MBP), MOG and DNA are produced with parallel suppression of antibodies hydrolysing histones.
|
30265424 |
2018 |
|
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A myelin basic protein (MBP)-induced experimental allergic encephalomyelitis (EAE) involves paraplegia due to a reversible thoracolumbar spinal cord impairment.
|
29224959 |
2018 |
|
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aspirin reduced the development of EAE driven by myelin basic protein (MBP)-specific T cells and the associated perivascular cuffing, inflammation, and demyelination.
|
30482850 |
2018 |
|
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In particular, cyclo(87-99)[Arg<sup>91</sup>, Ala<sup>96</sup>]MBP<sub>87-99</sub> was highly effective in preventing the onset and development of clinical symptoms and spinal cord pathology and providing lasting protection against EAE induction.
|
29385090 |
2018 |
|
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previously, we showed that myelin-reactive autoantibodies from patients with multiple sclerosis (MS) and mice with experimental autoimmune encephalomyelitis (EAE) exhibit the ability to recognize and hydrolyse distinct epitopes within myelin basic protein (MBP).
|
30139963 |
2018 |
|
Encephalomyelitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results showed: (1) diverse pathological features of long-term relapsing-remitting EAE; (2) relatively increased MBP and reduced β-APP expression in LA recipients 180 days after onset; (3) down-regulated TNF-α and up-regulated TGF-β levels in LA recipients 7 days after onset; (4) lower MDA and higher SOD levels in LA recipients 180 days after onset; (5) increased Treg levels in LA recipients 7 days after onset.
|
30338822 |
2018 |
|
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myelin basic protein (MBP) is a major target of T cells in lesions of multiple sclerosis (MS) patients and its animal model, experimental autoimmune encephalomyelitis (EAE).
|
28889362 |
2018 |
|
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study was designed to investigate the role of calpain and the proteasome in the removal of oxidized neuronal cytoskeletal proteins in myelin basic protein-induced experimental autoimmune encephalomyelitis (EAE).
|
30251207 |
2018 |
|
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used myelin basic protein (MBP)-proteolipid protein (PLP)-induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 (B6) mice as B cell-dependent model of MS. Mice were treated intraperitoneally either at the peak of EAE or at 60 days after onset with 200 μg murine anti-CD52 vs. IgG2a isotype control antibody for five consecutive days.
|
30098594 |
2018 |
|
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, the magnitudes of myelin basic protein (MBP)-induced rise in the frequency of IFN-γ+ and IL-17+ CD8+ T cells (providing important help to neuroantigen-specific CD4+ T cells in EAE models characterized by clinically mild disease) were greater in dLN cell cultures from aged AO rats.
|
29128575 |
2018 |
|
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
DHEA-S treatment also preserved myelin basic protein immunoreactivity and reduced axonal loss in animals with EAE, relative to vehicle-treated EAE animals.
|
28707358 |
2017 |
|
Encephalomyelitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Consistently, histopathological studies coupled with microscope-cellSens quantification and RT-qPCR analyzes showed that XBD173 prevented demyelination by restoring normal protein and mRNA levels of myelin basic protein that was significantly repressed in PLP-EAE mice spinal cord and brain.
|
28899788 |
2017 |
|
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we demonstrated that subcutaneously administered myelin basic protein (MBP)-pulsed CD11c+ bone marrow-derived dendritic cells (BMDC) were as effective at inducing EAE as subcutaneously administered MBP plus CFA.
|
27488372 |
2017 |
|
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Development and Pre-Clinical Evaluation of Recombinant Human Myelin Basic Protein Nano Therapeutic Vaccine in Experimental Autoimmune Encephalomyelitis Mice Animal Model.
|
28425447 |
2017 |
|
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, immunodominant MBP peptides encapsulated into the mannosylated liposomes, referred as Xemys, were shown to suppress development of experimental autoimmune encephalomyelitis, a rodent model of MS, and furthermore passed the initial stage of clinical trials.
|
29085375 |
2017 |
|
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using this approach, we demonstrate that antigen persistence is a dominant factor governing the elicitation of tolerance in the model of multiple sclerosis (MS), experimental autoimmune encephalomyelitis (EAE), induced by immunizing B10.PL mice with the N-terminal epitope of myelin basic protein.
|
27236506 |
2016 |
|
Encephalomyelitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
DAB(389)IL-2 in vitro treatment suppressed cytotoxicity of MBP-activated T cells from rats with EAE against oligodendrocytes in culture by 66%.
|
23872438 |
2014 |
|
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, Lewis rats immunized with myelin basic protein (MBP) 82-99 or MBP68-86 exhibited clinical signs of EAE and inflammatory infiltrates throughout CNS.
|
24388990 |
2014 |